Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orca Bio
Pharma
Orca Bio takes commercial leap with FDA approval for Tregzi
Orca Bio is charging the WAC of $428,000 for Tregzi, a novel regulatory T cell-based therapy for blood cancer patients requiring transplants.
Angus Liu
Jul 1, 2026 12:14am
FDA delays decision on Orca Bio’s cell therapy for blood cancers
Apr 1, 2026 8:00am
Orca rides $250M funding wave toward cancer cell therapy launch
Jan 9, 2026 11:19am
Cabaletta picks up the pace with new CCO from Legend, Celgene
Oct 14, 2025 12:42pm
Orca hires ex-Legend exec Gavel to target cell therapy market
Jun 5, 2025 11:58am
